Praziquantel Synergistically Enhances Paclitaxel Efficacy to Inhibit Cancer Cell Growth

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Wu, Zhen Hua ^a   Lu, Ming ke ^a   Hu, Long Yu ^a   Li, Xiaotong ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PRAZIQUANTEL; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MONOTHERAPY; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG SYNERGISM; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOSIS; NEOPLASMS; PACLITAXEL; PRAZIQUANTEL; TREATMENT OUTCOME; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84871207030     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051721     Document Type: Article

References (38)

1. Chong CR, Sullivan DJ Jr, (2007) New uses for old drugs. Nature 448: 645-646.
2. Boguski MS, Mandl KD, Sukhatme VP, (2009) Drug discovery. Repurposing with a difference. Science 324: 1394-1395.
3. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, et al. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354: 1021-1030.
4. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, et al. (2008) Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A 105: 11105-11109.
5. Ichim TE, Minev B, Braciak T, Luna B, Hunninghake R, et al. (2011) Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med 9: 25-37.
6. Fromberg A, Gutsch D, Schulze D, Vollbracht C, Weiss G, et al. (2011) Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol 67: 1157-1166.
7. Flossmann E, Rothwell PM, (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369: 1603-1613.
8. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, et al. (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376: 1741-1750.
9. Zhou H, Liu W, Su Y, Wei Z, Liu J, et al. (2010) NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell 17: 560-573.
10. Grosch S, Maier TJ, Schiffmann S, Geisslinger G, (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98: 736-747.
11. Haanen C, (2001) Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs 2: 677-683.
12. Woerdenbag HJ, Moskal TA, Pras N, Malingre TM, el-Feraly FS, et al. (1993) Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J Nat Prod 56: 849-856.
13. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR, (2001) The anti-malarial artesunate is also active against cancer. Int J Oncol 18: 767-773.
14. Hou J, Wang D, Zhang R, Wang H, (2008) Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 14: 5519-5530.
15. Nakase I, Lai H, Singh NP, Sasaki T, (2008) Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int J Pharm 354: 28-33.
16. Posner GH, Paik IH, Sur S, McRiner AJ, Borstnik K, et al. (2003) Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy. J Med Chem 46: 1060-1065.
17. Gonnert R, Andrews P, (1977) Praziquantel, a new board-spectrum antischistosomal agent. Z Parasitenkd 52: 129-150.
18. Keiser J, Utzinger J, (2007) Food-borne trematodiasis: current chemotherapy and advances with artemisinins and synthetic trioxolanes. Trends Parasitol 23: 555-562.
19. Brindley PJ, Sher A, (1987) The chemotherapeutic effect of praziquantel against Schistosoma mansoni is dependent on host antibody response. J Immunol 139: 215-220.
20. Joseph S, Jones FM, Walter K, Fulford AJ, Kimani G, et al. (2004) Increases in human T helper 2 cytokine responses to Schistosoma mansoni worm and worm-tegument antigens are induced by treatment with praziquantel. J Infect Dis 190: 835-842.
21. Jordan MA, Toso RJ, Thrower D, Wilson L, (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 90: 9552-9556.
22. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, et al. (1996) Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88: 1308-1314.
23. Jordan MA, Wilson L, (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265.
24. Rodriguez-Antona C, (2010) Pharmacogenomics of paclitaxel. Pharmacogenomics 11: 621-623.
25. Gottesman MM, (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627.
26. Aoki D, Oda Y, Hattori S, Taguchi K, Ohishi Y, et al. (2009) Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res 15: 1473-1480.
27. Qi Y, Fu X, Xiong Z, Zhang H, Hill SM, et al. (2012) Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. PLoS One 7: e31539.
28. Le XF, Mao W, He G, Claret FX, Xia W, et al. (2011) The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst 103: 1403-1422.
29. Harasawa R, Mizusawa H, Nozawa K, Nakagawa T, Asada K, et al. (1993) Detection and tentative identification of dominant mycoplasma species in cell cultures by restriction analysis of the 16S-23S rRNA intergenic spacer regions. Res Microbiol 144: 489-493.
30. Tang J, Hu M, Lee S, Roblin R, (1999) Primer mixture enhances PCR detection of Mycoplasma/Acholeplasma contaminants in cell cultures. In Vitro Cell Dev Biol Anim 35: 1-3.
31. Wu ZH, Hu LY, Xu DQ, Li X, (2012) A cell-based assay for screening spindle checkpoint inhibitors. Assay Drug Dev Technol 10: 344-352.
32. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, et al. (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527-536.
33. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, et al. (2007) Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11: 498-512.
34. Akiyoshi T, Nakamura M, Yanai K, Nagai S, Wada J, et al. (2008) Gamma-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology 134: 131-144.
35. Takeuchi H, Kim J, Fujimoto A, Umetani N, Mori T, et al. (2005) X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling. Clin Cancer Res 11: 7621-7628.
36. Schimmer AD, Dalili S, Batey RA, Riedl SJ, (2006) Targeting XIAP for the treatment of malignancy. Cell Death Differ 13: 179-188.
37. OConnor CL, Anguissola S, Huber HJ, Dussmann H, Prehn JH, et al. (2008) Intracellular signaling dynamics during apoptosis execution in the presence or absence of X-linked-inhibitor-of-apoptosis-protein. Biochim Biophys Acta 1783: 1903-1913.
38. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD, (2000) Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288: 874-877.